Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P23368
UPID:
MAOM_HUMAN
Alternative names:
Malic enzyme 2
Alternative UPACC:
P23368; B2R8J2; Q9BWL6; Q9BYG1; Q9H4B2
Background:
The NAD-dependent malic enzyme, mitochondrial, also known as Malic enzyme 2, plays a crucial role in cellular metabolism. It catalyzes the oxidative decarboxylation of malate to pyruvate, a key step in the citric acid cycle that powers cellular respiration.
Therapeutic significance:
Understanding the role of NAD-dependent malic enzyme, mitochondrial could open doors to potential therapeutic strategies.